Patents by Inventor David Shames
David Shames has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11674962Abstract: The present invention provides therapeutic, diagnostic, and prognostic methods for cancer. The invention provides methods of treating a cancer, methods of determining whether an individual having a cancer is likely to respond to a treatment including an immune checkpoint inhibitor (e.g., a PD-L1 axis binding antagonist), methods of predicting responsiveness of an individual having a cancer to a treatment including an immune checkpoint inhibitor (e.g., a PD-L1 axis binding antagonist), methods of selecting a therapy for an individual having a cancer, methods of providing a prognosis for an individual having a cancer, and methods of monitoring a response of an individual having a cancer, based on a blood tumor mutational burden (bTMB) score or a maximum somatic allele frequency (MSAF) from a sample (e.g., a whole blood sample, a plasma sample, a serum sample, or a combination thereof) from the individual.Type: GrantFiled: July 20, 2018Date of Patent: June 13, 2023Assignees: Genentech, Inc., Foundation Medicine, Inc.Inventors: Craig Anthony Cummings, Yan Li, Sarah Margaret Shagan, Erica Beth Schleifman, David Shames, David Fabrizio, Daniel Lieber, Geoffrey Alan Otto, Mark Kennedy, Travis Clark, Doron Lipson, Jie He, Shan Zhong
-
Publication number: 20220412981Abstract: The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma. The invention provides methods of treating cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma), methods of determining whether a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma) is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma) to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from cancer (e.g.Type: ApplicationFiled: March 4, 2022Publication date: December 29, 2022Inventors: David FABRIZIO, Garrett M. FRAMPTON, Priti HEGDE, Marcin KOWANETZ, David SHAMES, Philip J. STEPHENS, James Xin SUN, Roman YELENSKY, Wei ZOU
-
Patent number: 11300570Abstract: The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma. The invention provides methods of treating cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma), methods of determining whether a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma) is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma) to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from cancer (e.g.Type: GrantFiled: April 1, 2019Date of Patent: April 12, 2022Assignees: Genentech, Inc., Foundation Medicine, Inc.Inventors: David Fabrizio, Garrett M. Frampton, Priti Hegde, Marcin Kowanetz, David Shames, Philip J. Stephens, James Xin Sun, Roman Yelensky, Wei Zou
-
Patent number: 11261498Abstract: The present invention provides methods of treating cancer based on the methylation status of the ERBB2 gene. One aspect of the invention provides a method of administering an EGFR inhibitor therapy based on the methylation status of the ERBB2 gene.Type: GrantFiled: October 2, 2019Date of Patent: March 1, 2022Assignee: Genentech, Inc.Inventors: Thomas E. Januario, David Shames
-
Publication number: 20200024670Abstract: The present invention provides methods of predicting response to a cancer therapy based on the methylation status of the ERBB2 gene. One aspect of the invention provides a method of predicting response to an EGFR inhibitor therapy based on the methylation status of the ERBB2 gene.Type: ApplicationFiled: October 2, 2019Publication date: January 23, 2020Applicant: Genentech, Inc.Inventors: Thomas E. Januario, David Shames
-
Publication number: 20190219586Abstract: The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma. The invention provides methods of treating cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma), methods of determining whether a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma) is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma) to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from cancer (e.g.Type: ApplicationFiled: April 1, 2019Publication date: July 18, 2019Inventors: David Fabrizio, Garrett M. Frampton, Priti Hegde, Marcin Kowanetz, David Shames, Philip J. Stephens, James Xin Sun, Roman Yelensky, Wei Zou
-
Patent number: 10240207Abstract: The present invention concerns cancer biomarkers. In particular, the invention concerns HGF as a biomarker for patient selection and patient prognosis in cancer, as well as methods of therapeutic treatment, articles of manufacture and methods for making them, diagnostic kits, methods of detection and methods of advertising related thereto.Type: GrantFiled: September 21, 2016Date of Patent: March 26, 2019Assignee: Genentech, Inc.Inventors: Wei Yu, David Shames, Hartmut Koeppen, See Phan, Sandra Rost
-
Publication number: 20190025308Abstract: The present invention provides therapeutic, diagnostic, and prognostic methods for cancer. The invention provides methods of treating a cancer, methods of determining whether an individual having a cancer is likely to respond to a treatment including an immune checkpoint inhibitor (e.g., a PD-L1 axis binding antagonist), methods of predicting responsiveness of an individual having a cancer to a treatment including an immune checkpoint inhibitor (e.g., a PD-L1 axis binding antagonist), methods of selecting a therapy for an individual having a cancer, methods of providing a prognosis for an individual having a cancer, and methods of monitoring a response of an individual having a cancer, based on a blood tumor mutational burden (bTMB) score or a maximum somatic allele frequency (MSAF) from a sample (e.g., a whole blood sample, a plasma sample, a serum sample, or a combination thereof) from the individual.Type: ApplicationFiled: July 20, 2018Publication date: January 24, 2019Inventors: Craig Anthony CUMMINGS, Yan LI, Sarah Margaret PAUL, Erica Beth SCHLEIFMAN, David SHAMES, David FABRIZIO, Daniel LIEBER, Geoffrey Alan OTTO, Mark KENNEDY, Travis CLARK, Doron LIPSON, Jie HE, Shan ZHONG
-
Publication number: 20170306419Abstract: The present invention provides methods of predicting response to a cancer therapy based on the methylation status of the ERBB2 gene. One aspect of the invention provides a method of predicting response to an EGFR inhibitor therapy based on the methylation status of the ERBB2 gene.Type: ApplicationFiled: June 29, 2017Publication date: October 26, 2017Applicant: Genentech, Inc.Inventors: Thomas E. Januario, David Shames
-
Publication number: 20170183740Abstract: The present invention concerns cancer biomarkers. In particular, the invention concerns HGF as a biomarker for patient selection and patient prognosis in cancer, as well as methods of therapeutic treatment, articles of manufacture and methods for making them, diagnostic kits, methods of detection and methods of advertising related thereto.Type: ApplicationFiled: September 21, 2016Publication date: June 29, 2017Applicant: Genentech, Inc.Inventors: Wei YU, David SHAMES, Hartmut KOEPPEN, See PHAN, Sandra ROST
-
Publication number: 20150086543Abstract: The present invention provides methods of predicting response to a cancer therapy based on the methylation status of the ERBB2 gene. One aspect of the invention provides a method of predicting response to an EGFR inhibitor therapy based on the methylation status of the ERBB2 gene.Type: ApplicationFiled: November 24, 2014Publication date: March 26, 2015Applicant: GENENTECH, INC.Inventors: Thomas E. Januario, David Shames
-
Publication number: 20130259867Abstract: The present application describes the use of NRG1 overexpression as a selection criterion for treating cancer patients with a HER3 inhibitor, such as a bispecific HER3/EGFR inhibitor, and methods of treating those patients.Type: ApplicationFiled: March 15, 2013Publication date: October 3, 2013Applicant: GENENTECH, INC.Inventors: Lukas Amler, David Shames
-
Publication number: 20130084286Abstract: The present invention provides methods of predicting response to a cancer therapy based on the methylation status of the ERBB2 gene. One aspect of the invention provides a method of predicting response to an EGFR inhibitor therapy based on the methylation status of the ERBB2 gene.Type: ApplicationFiled: August 30, 2012Publication date: April 4, 2013Inventors: Thomas E. Januario, David Shames
-
Publication number: 20070111963Abstract: Synthesis of a target transcript of a gene is selectively increased in a mammalian cell by contacting the cell with a polynucleotide oligomer of 12-28 bases complementary to a region within a target promoter of the gene under conditions whereby the oligomer selectively increases synthesis of the target transcript.Type: ApplicationFiled: November 13, 2006Publication date: May 17, 2007Inventors: David Corey, Bethany Janowski, David Shames, John Minna